{
  "version": "1.0",
  "last_updated": "2026-02-15",
  "description": "Centralized FDA Pre-Submission question bank with 35+ questions across 10 categories",
  "questions": [
    {
      "id": "PRED-001",
      "category": "predicate_selection",
      "priority": 100,
      "text": "Does FDA agree that {predicate_k_numbers} ({predicate_device_names}) {is_are} an appropriate predicate device{s} for our {device_description_short}? If not, can FDA recommend alternative predicate(s)?",
      "applicable_meeting_types": ["formal", "written", "pre-ide"],
      "required_data": ["predicates"],
      "auto_populate": true,
      "rationale": "Core SE question - FDA must confirm predicate acceptability before submission strategy finalizes",
      "fda_guidance": "The 510(k) Program: Evaluating Substantial Equivalence (2014)"
    },
    {
      "id": "PRED-002",
      "category": "predicate_selection",
      "priority": 90,
      "text": "Our proposed predicate {primary_predicate_k_number} was cleared {years_ago} years ago. Does FDA recommend we consider more recent predicates, or is this acceptable given {similarity_rationale}?",
      "applicable_meeting_types": ["formal", "written"],
      "required_data": ["predicates", "predicate_age"],
      "triggers": ["old_predicate"],
      "auto_populate": true,
      "rationale": "Older predicates may have outdated testing expectations - FDA input prevents RTA"
    },
    {
      "id": "CLASS-001",
      "category": "classification",
      "priority": 95,
      "text": "We believe our device is appropriately classified under product code {product_code} (21 CFR {regulation_number}, Class {device_class}). Does FDA agree with this classification?",
      "applicable_meeting_types": ["formal", "written", "info", "pre-ide", "administrative"],
      "required_data": ["product_code", "regulation_number", "device_class"],
      "auto_populate": true,
      "rationale": "Classification confirmation is mandatory for all Pre-Subs - ensures regulatory pathway alignment",
      "fda_guidance": "CFR Title 21, Parts 862-892"
    },
    {
      "id": "CLASS-002",
      "category": "classification",
      "priority": 85,
      "text": "Our device has characteristics that may fall under multiple product codes ({product_codes_list}). Which product code does FDA recommend for classification?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["multi_product_code"],
      "required_data": ["product_codes_list"],
      "auto_populate": true,
      "rationale": "Product code ambiguity can delay review - early FDA determination prevents submission errors"
    },
    {
      "id": "TEST-BIO-001",
      "category": "testing_biocompatibility",
      "priority": 80,
      "text": "We propose biocompatibility testing per ISO 10993-1:2018 for {contact_type} contact with {contact_duration} duration. Does FDA agree this testing strategy is sufficient, or does FDA recommend additional endpoints?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["patient_contacting"],
      "required_data": ["contact_type", "contact_duration"],
      "auto_populate": true,
      "rationale": "Biocompatibility is critical safety concern for patient-contacting devices - FDA input reduces RTA risk",
      "fda_guidance": "Use of ISO 10993-1 (2016)"
    },
    {
      "id": "TEST-BIO-002",
      "category": "testing_biocompatibility",
      "priority": 75,
      "text": "Our device uses {materials_list}. Based on predicate precedent, we propose the following ISO 10993-1 endpoints: {proposed_endpoints}. Does FDA agree, or does FDA recommend additional testing?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["patient_contacting", "novel_materials"],
      "required_data": ["materials_list", "proposed_endpoints"],
      "auto_populate": true,
      "rationale": "Novel materials require comprehensive biocompatibility characterization - endpoint selection is critical"
    },
    {
      "id": "TEST-STER-001",
      "category": "testing_sterilization",
      "priority": 80,
      "text": "We propose sterilization validation per {sterilization_standard} using {sterilization_method}. Does FDA agree this approach is sufficient?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["sterile_device"],
      "required_data": ["sterilization_method", "sterilization_standard"],
      "auto_populate": true,
      "rationale": "Sterilization validation is critical for sterile devices - FDA must confirm method appropriateness",
      "fda_guidance": "Submission and Review of Sterility Information (2019)"
    },
    {
      "id": "TEST-SHELF-001",
      "category": "testing_shelf_life",
      "priority": 70,
      "text": "We propose a {shelf_life_years}-year shelf life supported by accelerated aging per ASTM F1980. Does FDA agree with this shelf life claim and testing approach?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["sterile_device", "shelf_life_claim"],
      "required_data": ["shelf_life_years"],
      "auto_populate": true,
      "rationale": "Shelf life claims require robust validation - FDA input on accelerated aging protocols prevents rejection"
    },
    {
      "id": "TEST-PERF-001",
      "category": "testing_performance",
      "priority": 75,
      "text": "We propose the following performance testing: {performance_tests_list}. Does FDA agree this testing adequately demonstrates device performance, or does FDA recommend additional tests?",
      "applicable_meeting_types": ["formal", "written"],
      "required_data": ["performance_tests_list"],
      "auto_populate": false,
      "rationale": "Performance testing expectations vary by device type - FDA alignment prevents costly re-testing"
    },
    {
      "id": "TEST-ELEC-001",
      "category": "testing_electrical",
      "priority": 80,
      "text": "We propose electrical safety testing per IEC 60601-1 and EMC testing per IEC 60601-1-2. Does FDA agree this approach is sufficient for our {device_type}?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["powered_device"],
      "required_data": ["device_type"],
      "auto_populate": true,
      "rationale": "Electrical safety is critical for powered devices - IEC 60601 series compliance is typically expected",
      "fda_guidance": "Recognition of IEC 60601-1:2005 (Third Edition)"
    },
    {
      "id": "TEST-SOFTWARE-001",
      "category": "testing_software",
      "priority": 85,
      "text": "Our device includes software with documentation level {software_level}. We propose software validation per IEC 62304 and usability engineering per IEC 62366-1. Does FDA agree this approach is sufficient?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["software_device"],
      "required_data": ["software_level"],
      "auto_populate": true,
      "rationale": "Software validation requirements are complex - early FDA alignment on documentation level prevents deficiencies",
      "fda_guidance": "Content of Premarket Submissions for Device Software Functions (2023)"
    },
    {
      "id": "TEST-CYBER-001",
      "category": "testing_cybersecurity",
      "priority": 80,
      "text": "Our device has {connectivity_type} connectivity. We propose cybersecurity validation per FDA's 2023 guidance. Does FDA agree with this approach, or does FDA recommend additional cybersecurity measures?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["connected_device"],
      "required_data": ["connectivity_type"],
      "auto_populate": true,
      "rationale": "Cybersecurity is mandatory for connected devices - FDA guidance (2023) requires specific documentation",
      "fda_guidance": "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (2023)"
    },
    {
      "id": "TEST-HF-001",
      "category": "testing_human_factors",
      "priority": 75,
      "text": "We propose human factors validation per IEC 62366-1 with {hf_study_type}. Does FDA agree this approach adequately addresses use-related risks identified in our risk analysis?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["complex_ui", "home_use"],
      "required_data": ["hf_study_type"],
      "auto_populate": false,
      "rationale": "Human factors is critical for devices with complex UI or home use - study design must address use errors",
      "fda_guidance": "Applying Human Factors and Usability Engineering to Medical Devices (2016)"
    },
    {
      "id": "CLINICAL-001",
      "category": "clinical_evidence",
      "priority": 85,
      "text": "Based on predicate precedent showing {clinical_precedent_summary}, does FDA expect clinical data for our submission? If so, what study design would FDA recommend?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "required_data": ["clinical_precedent_summary"],
      "auto_populate": false,
      "rationale": "Clinical data expectations vary widely by device type - FDA clarity prevents wasted resources",
      "fda_guidance": "Clinical Evidence for Clearance or Approval of Medical Devices (2022)"
    },
    {
      "id": "CLINICAL-002",
      "category": "clinical_evidence",
      "priority": 80,
      "text": "We propose to support our submission with clinical data from {clinical_data_source}. Does FDA consider this sufficient, or does FDA recommend a prospective clinical study?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "triggers": ["clinical_question"],
      "required_data": ["clinical_data_source"],
      "auto_populate": false,
      "rationale": "Prospective vs retrospective clinical evidence has different regulatory weight - FDA input is critical"
    },
    {
      "id": "CLINICAL-STUDY-001",
      "category": "clinical_study_design",
      "priority": 90,
      "text": "We propose a clinical study with the following design: {study_design_summary}. Does FDA agree with this approach, or does FDA recommend modifications to the study protocol?",
      "applicable_meeting_types": ["pre-ide"],
      "triggers": ["clinical_study_planned"],
      "required_data": ["study_design_summary"],
      "auto_populate": false,
      "rationale": "Clinical study protocol must be aligned with FDA expectations before initiation - prevents study failures"
    },
    {
      "id": "ENDPOINTS-001",
      "category": "clinical_study_design",
      "priority": 85,
      "text": "We propose the following primary endpoint: {primary_endpoint}. Does FDA agree this endpoint adequately demonstrates device safety and effectiveness?",
      "applicable_meeting_types": ["pre-ide"],
      "triggers": ["clinical_study_planned"],
      "required_data": ["primary_endpoint"],
      "auto_populate": false,
      "rationale": "Primary endpoint selection is critical for study success - FDA must confirm clinical relevance"
    },
    {
      "id": "IRB-001",
      "category": "clinical_study_design",
      "priority": 75,
      "text": "Do FDA and our IRB consider this device to be a significant risk (SR) or non-significant risk (NSR) device for the purposes of the proposed clinical study?",
      "applicable_meeting_types": ["pre-ide"],
      "triggers": ["clinical_study_planned"],
      "auto_populate": false,
      "rationale": "SR vs NSR determination affects IDE requirements - early FDA determination streamlines study initiation",
      "fda_guidance": "Significant Risk and Nonsignificant Risk Medical Device Studies (2006)"
    },
    {
      "id": "NOVEL-001",
      "category": "novel_technology",
      "priority": 90,
      "text": "Our device includes {novel_feature_description} not present in the proposed predicate. What additional data, if any, does FDA recommend to address this design difference?",
      "applicable_meeting_types": ["formal"],
      "triggers": ["novel_features"],
      "required_data": ["novel_feature_description"],
      "auto_populate": false,
      "rationale": "Novel features are primary SE barrier - early FDA input prevents costly testing mistakes",
      "fda_guidance": "The 510(k) Program: Evaluating Substantial Equivalence (2014), Section VI"
    },
    {
      "id": "NOVEL-002",
      "category": "novel_technology",
      "priority": 85,
      "text": "Given the novel {technology_aspect}, does FDA agree the 510(k) pathway remains appropriate, or should we consider the De Novo pathway?",
      "applicable_meeting_types": ["formal", "administrative"],
      "triggers": ["novel_features", "pathway_uncertainty"],
      "required_data": ["technology_aspect"],
      "auto_populate": false,
      "rationale": "Pathway determination is critical early decision - incorrect pathway wastes significant time and resources"
    },
    {
      "id": "IFU-001",
      "category": "indications_for_use",
      "priority": 80,
      "text": "Our proposed indications for use extend beyond the predicate to include {ifu_extension}. Does FDA consider this within the scope of substantial equivalence, or does FDA recommend narrowing the indications?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["ifu_extension"],
      "required_data": ["ifu_extension"],
      "auto_populate": false,
      "rationale": "IFU scope directly impacts SE determination - FDA must confirm acceptability of extensions"
    },
    {
      "id": "IFU-002",
      "category": "indications_for_use",
      "priority": 75,
      "text": "Does FDA agree our proposed indications for use ({proposed_ifu_summary}) are appropriately specific for a Class {device_class} device?",
      "applicable_meeting_types": ["formal", "written"],
      "required_data": ["proposed_ifu_summary", "device_class"],
      "auto_populate": true,
      "rationale": "IFU specificity requirements vary by device class - FDA input ensures regulatory alignment"
    },
    {
      "id": "LABEL-001",
      "category": "labeling",
      "priority": 70,
      "text": "Based on predicate labeling precedent, we propose the following key labeling elements: {labeling_elements}. Does FDA agree this labeling is adequate?",
      "applicable_meeting_types": ["formal", "written"],
      "required_data": ["labeling_elements"],
      "auto_populate": false,
      "rationale": "Labeling deficiencies are common RTA reason - early FDA review prevents rejection"
    },
    {
      "id": "LABEL-002",
      "category": "labeling",
      "priority": 65,
      "text": "Our device will include the following warnings and precautions: {warnings_list}. Does FDA recommend additional warnings based on the device risk profile?",
      "applicable_meeting_types": ["formal", "written"],
      "required_data": ["warnings_list"],
      "auto_populate": false,
      "rationale": "Warning adequacy is critical for risk mitigation - FDA input ensures comprehensive risk communication"
    },
    {
      "id": "MFG-001",
      "category": "manufacturing",
      "priority": 60,
      "text": "Our device will be manufactured at {manufacturing_location}. Does FDA foresee any regulatory concerns with this manufacturing location?",
      "applicable_meeting_types": ["formal", "written", "info"],
      "required_data": ["manufacturing_location"],
      "auto_populate": false,
      "rationale": "Manufacturing location can impact review timeline - early disclosure identifies potential issues"
    },
    {
      "id": "MFG-002",
      "category": "manufacturing",
      "priority": 55,
      "text": "We propose to make the following manufacturing changes compared to the predicate: {manufacturing_changes}. Does FDA consider these changes to impact substantial equivalence?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["manufacturing_difference"],
      "required_data": ["manufacturing_changes"],
      "auto_populate": false,
      "rationale": "Manufacturing changes can raise SE concerns - FDA input clarifies if validation data is needed"
    },
    {
      "id": "PATHWAY-001",
      "category": "regulatory_pathway",
      "priority": 95,
      "text": "Based on our analysis, we believe the {proposed_pathway} pathway is appropriate for this device. Does FDA agree, or does FDA recommend an alternative pathway?",
      "applicable_meeting_types": ["formal", "administrative"],
      "required_data": ["proposed_pathway"],
      "auto_populate": true,
      "rationale": "Pathway confirmation is fundamental decision - incorrect pathway wastes months of effort",
      "fda_guidance": "Is a 510(k) Required? (2019)"
    },
    {
      "id": "PATHWAY-002",
      "category": "regulatory_pathway",
      "priority": 85,
      "text": "Given the absence of {missing_element}, are there any special considerations or additional data FDA would recommend to support the {proposed_pathway} pathway?",
      "applicable_meeting_types": ["formal", "administrative"],
      "triggers": ["pathway_uncertainty"],
      "required_data": ["missing_element", "proposed_pathway"],
      "auto_populate": false,
      "rationale": "Pathway gaps (e.g., no clear predicate) require strategic FDA alignment"
    },
    {
      "id": "PATHWAY-003",
      "category": "regulatory_pathway",
      "priority": 80,
      "text": "We are considering both the 510(k) and De Novo pathways for this device. What factors should we prioritize in making this strategic decision?",
      "applicable_meeting_types": ["formal", "administrative"],
      "triggers": ["pathway_uncertainty"],
      "auto_populate": false,
      "rationale": "Strategic pathway selection requires FDA input when both options are viable"
    },
    {
      "id": "REPROCESS-001",
      "category": "reprocessing",
      "priority": 75,
      "text": "Our device is reusable and will be reprocessed {reprocessing_cycles} times. We propose reprocessing validation per {reprocessing_standard}. Does FDA agree this approach is sufficient?",
      "applicable_meeting_types": ["formal", "written"],
      "triggers": ["reusable_device"],
      "required_data": ["reprocessing_cycles", "reprocessing_standard"],
      "auto_populate": true,
      "rationale": "Reprocessing validation is critical for reusable devices - FDA guidance requires specific documentation",
      "fda_guidance": "Reprocessing Medical Devices in Health Care Settings (2015)"
    },
    {
      "id": "COMBO-001",
      "category": "combination_product",
      "priority": 85,
      "text": "Our device includes a {drug_component} component. We believe the device is the primary mode of action. Does FDA agree with this classification, or should we pursue a combination product designation?",
      "applicable_meeting_types": ["formal", "administrative"],
      "triggers": ["combination_product"],
      "required_data": ["drug_component"],
      "auto_populate": false,
      "rationale": "Combination product designation determines lead center (CDRH vs CDER) - early determination is critical",
      "fda_guidance": "Classification of Products as Drugs and Devices (2018)"
    },
    {
      "id": "STANDARDS-001",
      "category": "consensus_standards",
      "priority": 70,
      "text": "We propose to use the following FDA-recognized consensus standards: {standards_list}. Does FDA agree these standards adequately address the device-specific risks?",
      "applicable_meeting_types": ["formal", "written"],
      "required_data": ["standards_list"],
      "auto_populate": true,
      "rationale": "Standards selection must map to device risks - FDA confirmation ensures comprehensive testing coverage"
    },
    {
      "id": "TIMELINE-001",
      "category": "administrative",
      "priority": 50,
      "text": "We are planning to submit our 510(k) in {submission_timeline}. Are there any known review delays or backlogs for {product_code} devices that we should consider in our timeline planning?",
      "applicable_meeting_types": ["info", "administrative"],
      "required_data": ["submission_timeline", "product_code"],
      "auto_populate": true,
      "rationale": "Review timeline awareness supports strategic planning - FDA transparency on backlogs is valuable"
    },
    {
      "id": "PRIOR-INTERACTION-001",
      "category": "administrative",
      "priority": 60,
      "text": "We previously submitted {prior_submission_type} for a related device ({prior_k_number}). Are there any carryover considerations or lessons learned from that submission that FDA recommends we address?",
      "applicable_meeting_types": ["formal", "info"],
      "triggers": ["prior_submissions"],
      "required_data": ["prior_submission_type", "prior_k_number"],
      "auto_populate": false,
      "rationale": "Prior submission history can impact review approach - FDA input on carryover issues is valuable"
    }
  ],
  "meeting_type_defaults": {
    "formal": ["PRED-001", "CLASS-001", "TEST-BIO-001", "TEST-PERF-001", "NOVEL-001", "IFU-001", "PATHWAY-001"],
    "written": ["PRED-001", "CLASS-001", "TEST-BIO-001", "IFU-001"],
    "info": ["CLASS-001", "MFG-001"],
    "pre-ide": ["CLASS-001", "CLINICAL-STUDY-001", "ENDPOINTS-001", "IRB-001"],
    "administrative": ["CLASS-001", "PATHWAY-001", "PATHWAY-003"],
    "info-only": []
  },
  "auto_triggers": {
    "patient_contacting": ["TEST-BIO-001", "TEST-BIO-002"],
    "sterile_device": ["TEST-STER-001", "TEST-SHELF-001"],
    "powered_device": ["TEST-ELEC-001"],
    "software_device": ["TEST-SOFTWARE-001"],
    "connected_device": ["TEST-CYBER-001"],
    "novel_features": ["NOVEL-001", "NOVEL-002"],
    "clinical_study_planned": ["CLINICAL-STUDY-001", "ENDPOINTS-001", "IRB-001"],
    "ifu_extension": ["IFU-001"],
    "pathway_uncertainty": ["PATHWAY-002", "PATHWAY-003"],
    "reusable_device": ["REPROCESS-001"],
    "combination_product": ["COMBO-001"],
    "complex_ui": ["TEST-HF-001"],
    "home_use": ["TEST-HF-001"]
  },
  "categories": {
    "predicate_selection": "Questions about predicate device selection and acceptability",
    "classification": "Questions about device classification and product code",
    "testing_biocompatibility": "Biocompatibility testing strategy and ISO 10993 compliance",
    "testing_sterilization": "Sterilization validation and shelf life",
    "testing_shelf_life": "Shelf life claims and accelerated aging",
    "testing_performance": "Performance testing and functional validation",
    "testing_electrical": "Electrical safety and EMC testing (IEC 60601 series)",
    "testing_software": "Software validation and cybersecurity (IEC 62304, IEC 62366)",
    "testing_cybersecurity": "Cybersecurity for connected devices",
    "testing_human_factors": "Human factors and usability engineering",
    "clinical_evidence": "Clinical data requirements and study design",
    "clinical_study_design": "Clinical study protocol, endpoints, and IRB considerations",
    "novel_technology": "Novel features and technological characteristics",
    "indications_for_use": "IFU scope and specificity",
    "labeling": "Labeling content, warnings, and precautions",
    "manufacturing": "Manufacturing location and process changes",
    "regulatory_pathway": "Pathway selection (510k, De Novo, PMA)",
    "reprocessing": "Reprocessing validation for reusable devices",
    "combination_product": "Drug-device combination products",
    "consensus_standards": "FDA-recognized consensus standards selection",
    "administrative": "Administrative questions (timeline, prior interactions)"
  }
}
